Insights into neuro-ophthalmology

Neuro-ophthalmology stands at the intersection of ophthalmology and neurology and is often the final adjudication for complicated and complex cases. For neuro-ophthalmologists, the uncommon, unusual, and undiagnosed cases are the norm. The collection of articles in this issue is dedicated to neuro-ophthalmology and offers a glimpse into the myriad challenges faced by clinicians in the field.

Among the highlights of this special issue are monoclonal antibodies, an emerging and evolving therapeutic advance in medicine and neurology.[1] The articles delve into the realm of monoclonal antibody therapy, exploring its applications in aquaporin-4 immunoglobulin neuromyelitis optica spectrum disorder as well as other antibody-mediated neuro-ophthalmic disorders including myelin oligodendrocyte glycoprotein antibody-associated disease, myasthenia gravis, and thyroid eye disease.[2,3] In addition, a comprehensive review on monoclonal antibodies in neuro-ophthalmology sheds light on their evolving role in addressing challenging neuro-ophthalmic conditions. Furthermore, a dedicated exploration of immune checkpoint inhibition-related adverse effects emphasizes the importance of understanding the intricacies associated with these groundbreaking treatments.

The special issue also encompasses a spectrum of studies, ranging from the visual outcomes of methanol toxic optic neuropathy to the unique considerations in optic disc morphology and interocular symmetry in children.[4] Insights into the effects of oxaliplatin-induced papilledema and the acceleration of Moyamoya disease following anti-vascular endothelial growth factor intravitreal injections enrich the depth and diversity of this collection.[5]

In conclusion, this special issue on neuro-ophthalmology not only captures the essence of the field but also provides a platform for clinicians and researchers to explore, understand, and share the complexities inherent in the intricate relationship between vision and neurology. Despite its complexity, neuro-ophthalmology is considered an essential field for optimal ophthalmic and neurological care in societies, including Saudi Arabian societies, and we hope this special issue will enhance the interest of young ophthalmologists in this important field.[6] As we navigate through these articles and interesting cases, we gain valuable insights that contribute to the ongoing dialog within neuro-ophthalmology in all parts of the world.

Financial support and sponsorship

Nil.

Conflicts of interest

Prof. Lee works as a consultant for the following companies and organizations: the National Football League (NFL), the National Aeronautics and Space Administrations (NASA), Amgen, Alexion, Stoke, Viridian, AstraZeneca, and Bristol Myers Squibb.

Saif A. Alryalat[1,2], Osama Al Deyabat[1], Andrew G. Lee[1,3,4,5,6,7]

[1]Department of Ophthalmology, Blanton Eye Institute, Houston Methodist Hospital, [3]Department of Ophthalmology, Cullen Eye Institute, Baylor College of Medicine, [5]Department of Ophthalmology, University of Texas MD Anderson Cancer Center, Houston, [6]Texas A and M College of Medicine, Bryan, Texas, [4]Departments of Ophthalmology, Neurology, and Neurosurgery, Weill Cornell Medicine, New York, New York, [7]Department of Ophthalmology, The University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA, [2]Department of Ophthalmology, The University of Jordan, Amman, Jordan

Address for correspondence: Prof. Andrew G. Lee, Department of Ophthalmology, Blanton Eye Institute, Houston Methodist Hospital, 6560 Fannin Street 450, Houston, TX 77030, USA.
E-mail: aglee@houstonmethodist.org

Submitted: 21-Jan-2024
Accepted: 23-Jan-2024
Published: 29-Mar-2024

References

1. Novak JC, Lovett-Racke AE, Racke MK. Monoclonal antibody therapies and neurologic disorders. Arch Neurol 2008;65:1162-5.
2. Tisavipat N, Juan HY, Chen JJ. Monoclonal antibody therapies for aquaporin-4-immunoglobulin G-positive neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease. Saudi J Ophthalmol 2023.
3. Fatani WA, Hamdan DM, Taher NO, Alsharef JF, Aldubi RM, Alwagdani AM, *et al.* Monoclonal antibodies for the treatment of Graves' ophthalmopathy: A systematic review and meta-analysis. Saudi J Ophthalmol 2023;37:137-48.
4. Alrobaian M, Alkhuraiji A, Almohanna R, Alshehri M, Alyahya B. Visual outcome of methanol toxic optic neuropathy after erythropoietin treatment in Riyadh, Saudi Arabia. Saudi J Ophthalmol 2023;38:41-6.
5. Jayasri P, Stephen AM, Harigaravelu PJ. Oxaliplatin-induced papilledema: Rare case report. Saudi J Ophthalmol 2023;37:161-3.
6. Aldhahwani B. Neuro-ophthalmology in Saudi Arabia: Clinical practice, challenges, and future directions. Saudi J Ophthalmol 2020;34:40-4.

Access this article online	
Quick Response Code:	Website: www.saudijophthalmol.org
	DOI: 10.4103/sjopt.sjopt_27_24

How to cite this article: Alryalat SA, Al Deyabat O, Lee AG. Insights into neuro-ophthalmology. Saudi J Ophthalmol 2024;38:1.